Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: A randomized, double-blind, placebo-controlled study

Bipolar Disorders

Volumn 11, Issue 7, 2009, Pages 687-700

  Haas, Magali ^a   DelBello, Melissa P ^b   Pandina, Gahan ^c   Kushner, Stuart ^c   Van Hove, Ilse ^a   Augustyns, Ilse ^a   Quiroz, Jorge ^c   Kusumakar, Vivek ^c  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Adolescents; Bipolar disorder; Children; Mania; Risperidone

Indexed keywords

PLACEBO; RISPERIDONE;

ABDOMINAL PAIN; ADOLESCENT; AGGRESSION; AGITATION; ANXIETY; ARTICLE; ASTHMA; BIPOLAR DISORDER; BIPOLAR I DISORDER; BLURRED VISION; BRADYKINESIA; BRONCHOSPASM; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; DYSPEPSIA; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HUMAN; HYPERKINESIA; HYPERSALIVATION; INCREASED APPETITE; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MANIA; MANIC DEPRESSIVE PSYCHOSIS; MIXED MANIA AND DEPRESSION; MORNING DOSAGE; MULTICENTER STUDY; MUSCLE HYPERTONIA; MUSCULOSKELETAL STIFFNESS; NAUSEA; NERVOUSNESS; NOSE CONGESTION; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RISK BENEFIT ANALYSIS; SCHOOL CHILD; SIDE EFFECT; SOMNOLENCE; SORE THROAT; SPEECH DISORDER; STOMACH DISCOMFORT; SUICIDE ATTEMPT; TREATMENT DURATION; UPPER ABDOMINAL PAIN; VERTIGO; VOMITING; WEIGHT GAIN; YOUNG MANIA RATING SCALE;

ADOLESCENT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BODY MASS INDEX; CHILD; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; RISPERIDONE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 70350536654     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2009.00750.x     Document Type: Article

References (41)

1. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998, 50:143-151.
2. Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003, 73:123-131.
3. Soutullo CA, Chang KD, Diez-Suarez A. Bipolar disorder in children and adolescents: international perspective on epidemiology and phenomenology. Bipolar Disord 2005, 7:497-506.
4. Lewinsohn PM, Klein DN, Seeley JR. Bipolar disorders in a community sample of older adolescents: prevalence, phenomenology, comorbidity, and course. J Am Acad Child Adolesc Psychiatry 1995, 34:454-463.
5. Geller B, Zimerman B, Williams M. DSM-IV mania symptoms in a prepubertal and early adolescent bipolar disorder phenotype compared to attention-deficit hyperactive and normal controls. J Child Adolesc Psychopharmacol 2002, 12:11-25.
6. Geller B, Tillman R, Craney JL, Bolhofner K. Four-year prospective outcome and natural history of mania in children with a prepubertal and early adolescent bipolar disorder phenotype. Arch Gen Psychiatry 2004, 61:459-467.
7. Geller BR, Tillman R, Bolhofner K, Zimerman B. Child bipolar I disorder: prospective continuity with adult bipolar I disorder; characteristics of second and third episodes; predictors of 8-year outcome. Arch Gen Psychiatry 2008, 65:1125-1133.
8. McClellan J, Kowatch R, Findling RL. Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007, 46:107-125.
9. Birmaher B. Longitudinal course of pediatric bipolar disorder. Am J Psychiatry 2007, 164:537-539.
10. Wagner KD, Kowatch RA, Emslie GJ. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006, 163:1179-1186.
11. DelBello MP, Kowatch RA, Adler CM. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006, 45:305-313.
12. Hirschfeld RM, Keck PE, Kramer M. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004, 161:1057-1065.
13. Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005, 15:75-84.
14. Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 2005, 187:229-234.
15. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002, 159:1146-1154.
16. Yatham LN, Binder C, Kusumakar V, Riccardelli R. Risperidone plus lithium versus risperidone plus valproate in acute and continuation treatment of mania. Int Clin Psychopharmacol 2004, 19:103-109.
17. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006, 163:402-410.
18. McCracken JT, McGough J, Shah B. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002, 347:314-321.
19. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL. Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002, 159:1337-1346.
20. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A. Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002, 41:1026-1036.
21. Dunbar F, Kusumakar V, Daneman D, Schulz M. Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry 2004, 161:918-920.
22. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 2004, 161:677-684.
23. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M. Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 2006, 16:260-272.
24. Reyes M, Olah R, Csaba K, Augustyns I, Eerdekens M. Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. Eur Child Adolesc Psychiatry 2006, 15:97-104.
25. Shea S, Turgay A, Carroll A. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 2004, 114:e634-e641. http://www.pediatrics.org, [serial online], Available at: . Accessed October 1, 2007
26. Haas M, Eerdekens M, Kushner S. Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry 2009, 194:158-164.
27. Haas M, Unis A, Armanteros J, Copenhaver M, Quiroz J, Kushner S. A randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009
28. Biederman J, Mick E, Wozniak J, Aleardi M, Spencer T, Faraone SV. An open-label trial of risperidone in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2005, 15:311-317.
29. Frazier JA, Biederman J, Tohen M. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 2001, 11:239-250.
30. Pavuluri MN, Henry DB, Carbray JA, Sampson G, Naylor MW, Janicak PG. Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania. J Affect Disord 2004, 82(Suppl. 1):S103-S111.
31. Pavuluri MN, Henry DB, Carbray JA, Sampson GA, Naylor MW, Janicak PG. A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder. J Child Adolesc Psychopharmacol 2006, 16:336-350.
32. Kaufman J, Birmaher B, Brent D. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997, 36:980-988.
33. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-435.
34. Youngstrom EA, Danielson CK, Findling RL, Gracious BL, Calabrese JR. Factor structure of the Young Mania Rating Scale for use with youths ages 5 to 17 years. J Clin Child Adolesc Psychol 2002, 31:567-572.
35. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997, 73:159-171.
36. Hughes CW, Rintelmann J, Emslie GJ, Lopez M, MacCabe N. A revised anchored version of the BPRS-C for childhood psychiatric disorders. J Child Adolesc Psychopharmacol 2001, 11:77-93.
37. Guy WA. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology 1972, 534-537. Washington, DC, U.S. Department of Health, Education and Welfare
38. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, 212:11-19.
39. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989, 154:672-676.
40. Findling RL, Gracious BL, McNamara NK. Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. Bipolar Disord 2001, 3:202-210.
41. Tillman R, Geller B, Bolhofner K, Craney JL, Williams M, Zimerman B. Ages of onset and rates of syndromal and subsyndromal comorbid DSM-IV diagnoses in a prepubertal and early adolescent bipolar disorder phenotype. J Am Acad Child Adolesc Psychiatry 2003, 42:1486-1493.